HRPK20050421B3 - Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin - Google Patents

Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin

Info

Publication number
HRPK20050421B3
HRPK20050421B3 HR20050421A HRP20050421A HRPK20050421B3 HR PK20050421 B3 HRPK20050421 B3 HR PK20050421B3 HR 20050421 A HR20050421 A HR 20050421A HR P20050421 A HRP20050421 A HR P20050421A HR PK20050421 B3 HRPK20050421 B3 HR PK20050421B3
Authority
HR
Croatia
Prior art keywords
application
amphipats
aggregate
vivo
skin
Prior art date
Application number
HR20050421A
Other languages
English (en)
Croatian (hr)
Inventor
Cevc Gregor
Vierl Ulrich
Original Assignee
Idea Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/357,617 external-priority patent/US7473432B2/en
Application filed by Idea Ag filed Critical Idea Ag
Publication of HRP20050421A2 publication Critical patent/HRP20050421A2/hr
Publication of HRPK20050421B3 publication Critical patent/HRPK20050421B3/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Anesthesiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
HR20050421A 2002-10-11 2005-05-11 Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin HRPK20050421B3 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US41784702P 2002-10-11 2002-10-11
US10/357,617 US7473432B2 (en) 2002-10-11 2003-02-04 NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery
US10/357,618 US20040105881A1 (en) 2002-10-11 2003-02-04 Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
PCT/EP2003/011202 WO2004032900A1 (en) 2002-10-11 2003-10-09 Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin

Publications (2)

Publication Number Publication Date
HRP20050421A2 HRP20050421A2 (en) 2005-12-31
HRPK20050421B3 true HRPK20050421B3 (en) 2007-06-30

Family

ID=32995875

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20050421A HRPK20050421B3 (en) 2002-10-11 2005-05-11 Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin

Country Status (22)

Country Link
EP (5) EP1815846A3 (xx)
JP (3) JP2006505619A (xx)
KR (1) KR20050055723A (xx)
CN (1) CN1703199B (xx)
AT (1) ATE381316T1 (xx)
AU (1) AU2003273977B2 (xx)
BR (1) BR0315148A (xx)
CA (1) CA2498938A1 (xx)
DE (1) DE60318227T2 (xx)
DK (1) DK1551370T3 (xx)
EA (1) EA010407B1 (xx)
ES (1) ES2298566T3 (xx)
HK (1) HK1079113A1 (xx)
HR (1) HRPK20050421B3 (xx)
IS (1) IS7776A (xx)
MX (1) MXPA05003744A (xx)
NO (1) NO20052281L (xx)
NZ (1) NZ538571A (xx)
PL (1) PL377202A1 (xx)
PT (1) PT1551370E (xx)
SI (1) SI1551370T1 (xx)
WO (1) WO2004032900A1 (xx)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1031346T3 (da) 1999-01-27 2002-08-12 Idea Ag Ikke-invasiv vaccination gennem huden
PT1031347E (pt) 1999-01-27 2002-09-30 Idea Ag Transporte/imunizacao transnasal com veiculos muitissimo adaptaveis
CA2584475A1 (en) * 2004-11-12 2006-05-18 Idea Ag Extended surface aggregates in the treatment of skin conditions
EP2200651A2 (de) * 2007-09-13 2010-06-30 Basf Se Verwendung von hydrophobin-polypeptiden als penetrationsverstärker
PL214538B1 (pl) 2009-05-28 2013-08-30 P P F Hasco Lek Spolka Akcyjna Kompozycja liposomowa zawierajaca naproksen i sposób wytwarzania kompozycji liposomowej zawierajacej naproksen
CN105434354A (zh) * 2009-06-03 2016-03-30 斯昆申技术控股有限责任公司 用于治疗深部组织疼痛的制剂
JP2013502436A (ja) * 2009-08-21 2013-01-24 ターゲッティド デリバリー テクノロジーズ リミテッド 小胞状の製剤
GB2503844A (en) * 2011-03-21 2014-01-08 Gregor Cevc Drug-free compositions and methods for diminishing peripheral inflammation and pain
EP2688554A2 (en) * 2011-03-21 2014-01-29 Gregor Cevc Optimised preparations of highly adaptable aggregates
GB201205642D0 (en) 2012-03-29 2012-05-16 Sequessome Technology Holdings Ltd Vesicular formulations
JP6375301B2 (ja) * 2012-10-26 2018-08-15 オックスフォード ナノポール テクノロジーズ リミテッド 液滴界面
RU2524649C1 (ru) * 2013-07-24 2014-07-27 Станислав Анатольевич Кедик Способ получения микросфер для приготовления инъецируемой лекарственной формы диклофенака, композиция и лекарственная форма
SG11201600424VA (en) * 2013-07-31 2016-02-26 Sequessome Technology Holdings Ltd Vesicles
CN105764917B (zh) * 2013-09-26 2021-10-08 新加坡国立大学 利用溶血磷脂酰胆碱支架的组合物和方法
WO2015060446A1 (ja) * 2013-10-25 2015-04-30 凸版印刷株式会社 膜小胞回収デバイス、膜小胞回収方法、及び膜小胞分析方法
WO2017001625A1 (en) 2015-06-30 2017-01-05 Sequessome Technology Holdings Limited Multiphasic compositions
JP7280624B2 (ja) * 2017-04-03 2023-05-24 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 経血液脳関門的、経粘膜的及び経皮的薬物送達のための変形可能なナノスケールビヒクル(dnv)
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
KR102149190B1 (ko) 2018-04-09 2020-08-28 경상대학교산학협력단 액중 방전 마이크로젯 약물 전달장치
CN114206349A (zh) 2019-04-17 2022-03-18 指南针探路者有限公司 治疗神经认知障碍、慢性疼痛及减轻炎症的方法
CN115667217A (zh) 2020-05-19 2023-01-31 赛本爱尔兰有限公司 氘化的色胺衍生物和使用方法
KR102209397B1 (ko) 2020-07-21 2021-01-29 경상대학교산학협력단 액중 방전 마이크로젯 약물 전달장치

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6165500A (en) * 1990-08-24 2000-12-26 Idea Ag Preparation for the application of agents in mini-droplets
DE4107153A1 (de) * 1991-03-06 1992-09-10 Gregor Cevc Praeparat zur wirkstoffapplikation in kleinsttroepfchenform
CA2067754C (en) * 1990-08-24 2002-06-04 Gregor Cevc Preparation for the application of agents in mini-droplets
DE4447277A1 (de) * 1994-12-30 1996-07-04 Hoechst Ag Stabilisierte, phosphormodifizierte Epoxidharze und ihre Verwendung
DE4447287C1 (de) * 1994-12-30 1996-11-07 Cevc Gregor Präparat zum Wirkstofftransport durch Barrieren
US20020048596A1 (en) * 1994-12-30 2002-04-25 Gregor Cevc Preparation for the transport of an active substance across barriers
EP1140021B1 (en) * 1998-12-23 2004-08-04 Idea Ag Improved formulation for topical non-invasive application in vivo
PT1031347E (pt) * 1999-01-27 2002-09-30 Idea Ag Transporte/imunizacao transnasal com veiculos muitissimo adaptaveis

Also Published As

Publication number Publication date
PT1551370E (pt) 2008-02-07
EP1815846A2 (en) 2007-08-08
HK1079113A1 (en) 2006-03-31
JP2005213261A (ja) 2005-08-11
CN1703199A (zh) 2005-11-30
SI1551370T1 (sl) 2008-06-30
AU2003273977A1 (en) 2004-05-04
EP1815846A3 (en) 2008-10-22
BR0315148A (pt) 2005-08-16
CA2498938A1 (en) 2004-04-22
DK1551370T3 (da) 2008-03-03
EP1829528A2 (en) 2007-09-05
WO2004032900A1 (en) 2004-04-22
DE60318227T2 (de) 2008-12-04
EP1551370B1 (en) 2007-12-19
ATE381316T1 (de) 2008-01-15
HRP20050421A2 (en) 2005-12-31
NO20052281D0 (no) 2005-05-10
EP1551370A1 (en) 2005-07-13
EP1829527A2 (en) 2007-09-05
AU2003273977B2 (en) 2007-07-12
JP2006505619A (ja) 2006-02-16
CN1703199B (zh) 2010-04-28
PL377202A1 (pl) 2006-01-23
NZ538571A (en) 2007-05-31
EP1815847A2 (en) 2007-08-08
ES2298566T3 (es) 2008-05-16
EP1815847A3 (en) 2008-11-05
MXPA05003744A (es) 2005-09-20
EP1829528A3 (en) 2008-11-05
JP4555111B2 (ja) 2010-09-29
IS7776A (is) 2005-03-30
JP2009108070A (ja) 2009-05-21
EP1829527A3 (en) 2008-11-05
KR20050055723A (ko) 2005-06-13
WO2004032900A8 (en) 2005-03-31
DE60318227D1 (de) 2008-01-31
NO20052281L (no) 2005-07-07
EA010407B1 (ru) 2008-08-29
EA200500632A1 (ru) 2005-12-29

Similar Documents

Publication Publication Date Title
HRPK20050421B3 (en) Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
UA83350C2 (ru) Агрегат с повышенной способностью к деформации, который содержит по крайней мере три амфипатические вещества, для улучшеной транспортировки через полупроницаемые барьеры и для неинвазивного применения лекарственного средства in vivo, в частности через кожу
Johnson et al. Diagnosis and treatment of acute urinary tract infections
WO2005000161A3 (en) Methods and devices for occluding body lumens and/or for delivering therapeutic agents
ATE89717T1 (de) Traeger zur freisetzung mit einem an eine amphiphile substanz gekoppelten wirkstoff.
CA2330207A1 (en) Microneedle devices and methods of manufacture and use thereof
PT977555E (pt) Preparacoes farmaceuticas e metodos para a sua administracao localmente
JP2004536045A5 (xx)
CA2387873A1 (en) Nordihydroguaiaretic derivatives for use in treatment of tumors
WO1999056723A3 (en) Hemoglobine-haptoglobin complexes for targeted drug delivery
EE200100388A (et) Püridasino [4,5-b] indool-1-atseetamiidi derivaatide kasutamine ravimite valmistamiseks perifeersete bensodiasepiiniretseptorite düsfunktsioneerimisega seotud haiguste raviks
AUPQ879500A0 (en) Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
WO2000072823A8 (en) Preparations for the application of anti-inflammatory agents
WO2004004705A3 (en) Pharmaceutical formulations for preparing drink products
Labi et al. The Grief Brigade.
FR2572932B1 (fr) Medicament insoluble administre localement dans l'oreille
ES2135476T3 (es) Utilizacion de remacemida para el tratamiento de la enfermedad de parkinson.
WO2001017582A3 (en) Bifurcated shunt drug delivery system and methods of use
Boulton Combination drug treatment benefits patients with HIV.
Wheeler RG-1068 RepliGen
Cadman On the road with protease inhibitors
RU2002127274A (ru) Применение препарата ветом-7048 впервые в качестве лекарственного препарата при лечении атрофии мозга, гидроцефалии мозга
HUP0402242A3 (en) Use of 4-oxobutanoic acid derivatives in the treatment of inflammation
GC0000336A (en) Pharmaceutical formulation comprising amoxycillin and clavulanate for the treatment of drug resistant s.pneumoniae
RU97105491A (ru) Способ приживления кожных тканей при пластических операциях

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AKOB Publication of a request for the grant of a patent not including a substantive examination of a patent application (a consensual patent)
PKB1 Consensual patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20110722

Year of fee payment: 9

PBKO Lapse due to non-payment of renewal fee for consensual patent

Effective date: 20121010